Raptor Pharmaceutical Corp

Raptor Pharmaceutical

WKN: A0YBWE / ISIN: US75382F1066

eröffnet am:	20.02.14 07:03 von:	Capret
neuester Beitrag:	12.09.16 23:35 von:	Heron
Anzahl Beiträge:	21
Leser gesamt:	8013
davon Heute:	5
bewertet mit 13 Sternen


Antwort einfügen
zum neuesten Beitrag
Börsenforum

Raptor Pharmaceutical Corp Raptor Pharmaceutical Corp. (Nasdaq:RPTP) ('Raptor') hat es sich zur Aufgabe gemacht, Arzneimittel zu entwickeln, herzustellen und zu vermarkten, die das Leben von Patienten mit schweren, seltenen Krankheiten verbessern. Raptor arbeitet derzeit an der klinischen Entwicklung von Produktkandidaten zur Behandlung von nephropathischer Cystinose, nichtalkoholischer Fettleberhepatitis ('NASH'), Huntington-Krankheit ('HK'), Aldehyddehydrogenase-Mangel ('ALDH2') und thrombotischen Storungen.

Die praklinischen Programme von Raptor basieren auf biotechnisch hergestellten, neuartigen Arzneimittelkandidaten und Drug-Targeting-Plattformen, die aus dem humanen rezeptorassoziierten Protein sowie verwandten Proteinen abgeleitet sind und gegen Krebs und Infektionskrankheiten eingesetzt werden sollen.

Pipeline

Overview & Pipeline

http://www.raptorpharma.com/pipeline

Angehängte Grafik:
rap_pipe.png (verkleinert auf 45%)

Raptor Announces Clinical Results

Raptor Announces Clinical Results With RP103 in Huntington's Disease Phase 2/3 Trial | Benzinga

Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced top line results from a planned 18 month analysis of an ongoing 3 year Phase 2/3 clinical trial ...

http://www.benzinga.com/news/14/02/4323569/...s-disease-phase-23-tria

Raptor extended hours ging gestern Abend schon hoch, mal auf den Haupthandel gespannt

Angehängte Grafik:
rep.png (verkleinert auf 37%)

Geht noch mehr?

Angehängte Grafik:
rap2.png (verkleinert auf 64%)

Volumen ist awesome! und das im pre! :D

Angehängte Grafik:
rap3.png (verkleinert auf 66%)

Nette slideshow

Angehängte Grafik:
rap4.png (verkleinert auf 66%)

Why Raptor Shares Clawed Higher

Why Raptor Pharmaceuticals Corp. Shares Clawed Higher (RPTP)

Raptor shares climbed after releasing interim data for its ongoing phase 2/3 trial for RP103, a treatment for Huntington's disease. Is it time to break out the pom-poms? - Sean Williams - Health Care

http://www.fool.com/investing/general/2014/02/20/...-clawed-high.aspx

Raptor Pharmaceutical to Present

Raptor Pharmaceutical to Present at Two Upcoming Investor Conferences - NASDAQ.com

Raptor Pharmaceutical Corp. today announced that company management will present at two upcoming investor conferences. About Raptor Pharmaceutical..

http://www.nasdaq.com/press-release/...tor-conferences-20140224-00345

Raptor Pharmaceutical Corp. Downgraded

Raptor Pharmaceutical Corp. Downgraded by Ladenburg Thalmann to Neutral (RPTP) | Zolmax

Ladenburg Thalmann cut shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) from a buy rating to a neutral rating in a research report sent to investors on

http://zolmax.com/investing/...nburg-thalmann-to-neutral-rptp/218868/

Short Interest Up 21.5% in February

Raptor Pharmaceutical Corp. Short Interest Up 21.5% in February (RPTP) | Zolmax

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) was the recipient of a large increase in short interest in the month of January. As of February 14th, there was s

http://zolmax.com/investing/...erest-up-21-5-in-february-rptp/224525/

Upgrades Raptor Pharmaceutical Corp. to Hold

Thomson Reuters/Verus Upgrades Raptor Pharmaceutical Corp. to Hold (RPTP) | WKRB News

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) was upgraded by investment analysts at Thomson Reuters/Verus from a "sell" rating to a "hold" rating in a note is

http://www.wkrb13.com/markets/272244/...maceutical-corp-to-hold-rptp/

Upcoming Event Mar 4, 2014 9:20 AM ET

Cowen and Company, 34th Annual Health Care Conference
Speaker: Christopher Starr, Ph.D., Chief Executive Officer

Webcast:

Cowen and Company 34th Annual Health Care Conference

http://wsw.com/webcast/cowen16/...ttp://wsw.com/webcast/cowen16/rptp/

Data Published
Data Published in Journal of Pediatrics Demonstrated That PROCYSBI(R) Improved Quality of Life and Preserved Kidney Function in Cystinosis Patients

Data Published in Journal of Pediatrics Demonstrated That PROCYSBI(R) Improved Quality of Life and Preserved Kidney Function in Cystinosis Patients - MarketWatch

http://www.marketwatch.com/story/...in-cystinosis-patients-2014-06-24

Drug Designation In EU

Raptor Pharma: Cysteamine Bitartrate Gets Orphan Drug Designation In EU

http://www.rttnews.com/2362630/...-orphan-drug-designation-in-eu.aspx

Upcoming Investor Conference

Raptor Pharmaceutical to Present at Upcoming Investor Conference in September - MarketWatch

http://www.marketwatch.com/story/...onference-in-september-2014-08-27

... Raptor Pharma legt Studiendaten zu CyNCh vor (Phase 2b), gewünschte Resultate wurden nicht erzielt

... Citigroup stuft Raptor Pharma von buy auf neutral und senkt das Kursziel von $20 auf $8

... http://www.fool.com/investing/general/2016/04/07/...e=iedfolrf0000001

$9.00 in cash http://ih.advfn.com/...pid=nmona&article=72412163&symbol=RPTP

Merger Announced Acquisition of Raptor Pharmaceutical Corp.
Further Strengthens Horizon Pharma’s Focus on Rare Diseases

http://files.shareholder.com/downloads/AMDA-IWPVT/...armaceutical.pdf

September 12, 2016

Antwort einfügen - nach oben